Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 11 of 11 for “"pembrolizumab"”.
-
The Microsatellite Instability High Endometrial Tumor Microenvironment and Identifying Predictive Biomarkers of Response to Pembrolizumab
… endometrial cancer are treatment-refractory to pembrolizumab. We sought to evaluate the MSI-H endometrial tumor samples to examine differences in the tumor microenvironment (TME) and identify transcriptomic signatures associated with response/resistance to pembrolizumab. Methods: Archival tumor …
-
Genotoxic effects in human peripheral lymphocytes from healthy individuals and head and neck cancer patients after treatment with hydrogen peroxide and pembrolizumab liposome
… carcinogens and alcohol consumption. Pembrolizumab has shown to be effective in the treatment of many types of cancers such as melanoma, non-small cell lung cancer, due to its antiproliferative, immunoregulatory properties. The aim of this study was to investigate the effects of naked …
-
Novel Immunotherapy Agents in Oncology: Generalizability of Trial Results and Drivers of Clinical Utilization
… Novel immunotherapy agents such as nivolumab and pembrolizumab have become an essential, albeit extremely expensive, component of oncology care since their first approvals in melanoma in 2014 and lung cancer in 2015. However, little is known about differences between immunotherapy clinical trial …
-
An Affinity Threshold for Maximum Efficacy in Anti-PD-1 Cancer Immunotherapy
… FDA-approved anti-PD-1 antibodies, nivolumab and pembrolizumab have similar single digit nanomolar equilibrium binding constants (KD). Anti-PD-1 antibodies with higher and lower affinity than nivolumab or pembrolizumab are entering the clinic and show varied pre-clinical efficacy. Here, we explore …
-
AXL Targeting Restores PD-1 Blockade Sensitivity of STK11/LKB1 Mutant NSCLC Through Expansion of TCF1+ CD8 T Cells
… the combination of AXL inhibitor bemcentinib and pembrolizumab. We conclude that AXL is a critical targetable driver of immune suppression in STK11/LKB1 mutant NSCLC.
-
Computational imaging and multiomic biomarkers for precision medicine: characterizing heterogeneity in lung cancer.
… anti-PD1/PDL1 checkpoint inhibitor therapy PEMBROLIZUMAB. This study also showed that mitigation of the heterogeneity introduced by voxel spacing and image acquisition parameters improves the prognostic performance of the radiomic phenotypes. We further performed a detailed investigation of …
-
Ανοσοθεραπεία κατόπιν της εμφάνισης προόδου νόσου σε διπλή ανοσοθεραπεία: Πεμπρολιζουμάμπη και Λενβατινίμπη έναντι συμβατικής χημειοθεραπείας σε ασθενείς με μεταστατικό μελάνωμα κατόπιν αποτυχίας αναστολής των PD-1/CTLA-4 σημείων ελέγχου του ανοσοποιητικού / Immunotherapy after progression to double immunotherapy: Pembrolizumab and Lenvatinib versus conventional chemotherapy for patients with metastatic melanoma after failure of PD-1/CTLA-4 inhibition
… ότι η χορήγηση του συνδυασμού Πεμπρολιζουμάμπης (Pembrolizumab)/Λενβατινίμπης (Lenvatinib) ενδέχεται πιθανώς, να υπερκεράσει την ανθεκτικότητα στην ανοσοθεραπεία με αναστολείς PD-1/CTLA-4. Ελλείψει της παρουσίας προοπτικής συγκριτικής μελέτης και προκειμένου να αξιολόγηθεί, σε πραγματικές κλινικές …
-
Ανοσοθεραπεία στο καρκίνο κεφαλής και τραχήλου: μία συστηματική ανασκόπηση / Immunotherapy in head and neck cancer : a systematic review
… των ανοσολογικών σημείων ελέγχου, όπως το Pembrolizumab και το Nivolumab, οι οποίοι έχουν ενταχθεί στη θεραπευτική στρατηγική του υποτροπιάζοντος ή μεταστατικού καρκίνου κεφαλής και τραχήλου, παρουσιάζοντας βελτίωση στη συνολική επιβίωση και σε ορισμένες περιπτώσεις πιο ευνοϊκό προφίλ …
-
Unravelling the potential applications of extracellular vesicles for the clinical management of melanoma patients
… plasma of melanoma patients being treated with pembrolizumab was used to isolate EV-RNA to identify a transcriptional signature predictive of response. Lastly, Chapter 5 provides a general discussion of the studies presented in this thesis. Altogether, the results of these studies underscore the …
-
Development of Microfluidic 3D Cell Array with Tumor-Stroma interaction for Cancer Immunotherapy Drug Screening
… all the breast cancer subtypes. Atezolizumab and pembrolizumab, two antibody drugs targeting the PD-L1/PD-1 pathway, have been approved by FDA in combination with chemo drugs for certain TNBC cases in 2019 and 2020, respectively. These facts reveal the feasibility of immunotherapy in treating …
-
NOVEL MONO-, BI- AND TRI-SPECIFIC IMMUNOMODULATORY ANTIBODIES FOR CANCER THERAPY AND TOOLS FOR OTHER THERAPEUTIC AND DIAGNOSTIC APPLICATIONS
… to those of validated mAbs (Atezolizumab, Pembrolizumab or Relatlimab) and, more interestingly, an increased ability to induce lymphocyte activation and stronger in vitro tumor cytotoxicity compared to the combination of clinically validated mAbs. In parallel, with the aim of recruiting T …